The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

By R. Nahta, M. Hung, F. Esteva. Cancer Research, 2004

615 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/5855fbc0a52742971ce75cff7005135d959e0ac0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Aglietta
2. G. Valabrega
3. F. Montemurro
4. R. Nahta
5. A. Takaoka
6. K. Imai
7. S. Swain
8. M. Hung

In Radiology, Nuclear Medicine and Imaging

1. M. Aglietta
2. G. Valabrega
3. F. Montemurro
4. R. Nahta
5. K. Imai
6. A. Takaoka
7. J. Baselga
8. S. Swain

Citations in the corpus

• Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. (2005, background): “Phosphorylation of Akt, which lies downstream of HER-2, was reduced in resistant cells whereas MAPK phosphorylation was unaffected, which is consistent with results observed in another HER-2-overxpressing breast cancer cell line (12).”
• Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer (2006, background): “Therapy with trastuzumab plus pertuzumab synergized to induce apoptosis in HER2-overexpressing trastuzumab-naive breast cancer cells”
• Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. (2007, methodology): “Preclinical data were also obtained from the combination of trastuzumab and pertuzumab (2C4, Genentech Inc, South San Francisco, CA, USA) [57].”
• Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. (2009, methodology): “The synergistic action of trastuzumab and pertuzumab combination treatment was previously shown in vitro (30) using the calculation of the combination index as outlined by Chou and Talalay (35, 36).”
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009, background): “Interestingly, the combination of pertuzumab with trastuzumab has been shown to synergistically inhibit the survival of breast tumour cells in preclinical studie”
• Comparing antibody and small-molecule therapies for cancer (2006, result): “Our results showed that it is significantly more effective than trastuzuma”